At the IGTP TODAY

News

- Research

In vitro development of a new personalized therapy for patients with neurofibromatosis type 2

Researchers from the Clinical Genomics group of the Germans Trias i Pujol Research Institute (IGTP) and the Genetics Service of the Germans Trias Hospital (HUGTiP) have developed a new in vitro therapy to recover part of the function encoded by the gene NF2, which, when altered, induces the development of neurofibromatosis type 2. The study has been published in the prestigious journal Molecular Therapy Nucleic Acids.

- Research

A study of more than 750 healthcare professionals confirms that antibodies persist 17 months after having suffered from COVID-19

  • Research has also confirmed that people who suffered from the disease in a serious way generate more antibodies than those who had moderate and mild effects.
  • The results of this study show significant differences in the generation of antibodies between men and women on day 30 of infection and for all antibodies measured.
  • This is one of the largest studies carried out to date in Catalonia, both in terms of the volume of participants and the length of follow-up.
- Research

A diet rich in plant-based omega-3 is associated with better outcomes in heart failure patients

Higher levels of plant-based omega-3 fats reduce the risk of death and hospital admission in people with heart failure. This is according to a joint study by researchers at Germans Trias i Pujol Hospital and Research Institute and the Hospital del Mar Medical Research Institute, published in the Journal of the American College of Cardiology, involving the follow-up of almost a thousand patients.

- Projects, Research

Research impulse into hepatoblastoma, the main childhood liver cancer

A collaborative CIBER project will boost hepatoblastoma (HB) research to identify new therapeutic targets that will allow strategies to be developed to improve the prognosis of those children who currently do not survive the disease. The project coordinated by Carolina Armengol, principal CIBEREHD researcher at the Germans Trias i Pujol Research Institute (IGTP) is a collaboration between 5 CIBER groups belonging to the Hepatic and Digestive Diseases area (CIBEREHD) and the Cancer area (CIBERONC).

- Research

Mesenchymal stem cells reveal mechanisms of action in regulatory B cells independent of interleukin-10 useful for their identification and monitoring

Researchers from the REMAR-IVECAT ("Kidney Related Diseases Research" and "Innovation in VEsicles and Cells for Application in Therapy") group, from the Germans Trias i Pujol Research Institute (IGTP), identify molecular pathways in regulatory B cells that are essential for their therapeutic applications. In the article that has been recently published in Frontiers in Immunology, the use of mesenchymal stem cells has allowed distinguishing the molecules that are essential to monitoring regulatory B cells in kidney transplants. 

- Research

Largest genetic study on stroke to date improves risk prediction

  • A group of investigators from the Research Institute of the Hospital de la Santa Creu i Sant Pau - IIB Sant Pau has led the analysis of Spanish data from the largest international study carried out to date on the genetics of stroke risk.
  • The results, published by the prestigious journal Nature, allow us to predict, with much more precision, the risk that a person may suffer a stroke. In addition, they provide valuable information on the biological processes involved in this disease, which is helping to find new, more effective treatments.
  • The study analyzed data from the International Stroke Genetics Consortium, of which the Spanish Genestroke consortium is a member, and the GCAT|Genomes for Life cohort, from the Germans Trias i Pujol Research Institute (IGTP).